<DOC>
	<DOCNO>NCT00210028</DOCNO>
	<brief_summary>The purpose study evaluate objective response rate ZARNESTRA add treatment tamoxifen</brief_summary>
	<brief_title>Study Assessing Efficacy ZARNESTRA™ Combined With Tamoxifen Patients With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Histologically proven , metastatic locally advance inoperable breast cancer Tumor consider potentially hormonesensitive , i.e . presence IHC hormone receptor estrogens ( ER+ 10 % cell ) and/or progesterone ( Pg+ 10 % cell ) . This expression may detect primary tumor metastatic site . The method use reassess IHC involve radioligand technique whenever possible obtain histological material . Progressing treatment tamoxifen , give either adjuvant treatment advanced/metastatic breast cancer . Any previous treatment steroidal nonsteroidal antiaromatase neoadjuvant , adjuvant metastatic situation permit . Likewise , previous treatment chemotherapy and/or herceptin nonmetastatic situation permit . Postmenopausal patient Age &gt; 18 year At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ; patient bone metastasis , evaluable nonirradiated lytic lesion require Performance Status ( WHO ) : PS ≤ 2 ( Appendix 1 ) . Laboratory test accordance follow criterion : Neutrophils ≥ 2x109/l , Platelets ≥ 100x109/l , Hemoglobin ≥ 10 g/dl , ASAT , ALAT ≤ 2.5 N , &lt; 5 N liver metastasis , bilirubin ≤ 1.5 N creatinin ≤ 1.5 N Signed , write consent studyrelated procedure Men Premenopausal patient receive concurrent LHRH agonist therapy ER PRnegative patient Contraindication antiestrogens ( thromboembolic risk ) ZARNESTRA Non metastatic tumor susceptible management radiotherapeutic and/or surgical mean T4d inflammatory tumor ( PEV 2 3 ) . Shortterm , lifethreatening lesion : hepatic invasion &gt; 1/3 liver volume , pulmonary lymphangitis , uncontrolled cerebral metastasis , carcinomatous meningitis Sensory neuropathy &gt; = grade 1 ( WHO ) Previous history uncontrolled cancer control less 5 year , except basal cell skin cancer situ cancer cervix . Chronic disease ( somatic psychiatric ) poor prognosis subject enzymeinducing anticonvulsant ( e.g. , phenytoin , phenobarbital , carbamazepine ) : treatment permit take ZARNESTRA Patients , family , social , geographic psychological reason , could follow correctly .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Zarnestra</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>estrogen receptor</keyword>
	<keyword>progesterone receptor</keyword>
</DOC>